Evidence map›Paper›PMID 29714124›Full record

ArticlePersonalized medicine2018

Clinical application of pharmacogenetics in pain management.

D Max Smith, Kristin W Weitzel, Larisa H Cavallari, Amanda R Elsey, Siegfried Of Schmidt

Abstract read
In one paragraph

Article in Personalized medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The Role of Pharmacogenomics in Postoperative Pain Management.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  10. Article
  11. Different Pharmacokinetics of Tramadol,Frontiers in pharmacology · 2021
    Article
  12. Review
  13. Article
  14. Article
  15. Genetics of perioperative pain management.Current opinion in anaesthesiology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

D Max SmithDepartment of Pharmacotherapy & Translational Research, University of Florida, PO Box 100486, Gainesville, FL 32610-0486, USA.
Kristin W WeitzelDepartment of Pharmacotherapy & Translational Research, University of Florida, PO Box 100486, Gainesville, FL 32610-0486, USA.
Larisa H CavallariDepartment of Pharmacotherapy & Translational Research, University of Florida, PO Box 100486, Gainesville, FL 32610-0486, USA.
Amanda R ElseyDepartment of Pharmacotherapy & Translational Research, University of Florida, PO Box 100486, Gainesville, FL 32610-0486, USA.
Siegfried Of SchmidtDepartment of Community Health & Family Medicine, College of Medicine University of Florida, 200 SW 62nd Blvd Suite D Gainesville, FL 32607, USA.

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR001427NHGRI NIH HHS U01 HG007269NHLBI NIH HHS U01 HL105198NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

There is growing experience translating genomic data into clinical practice, as seen with the Implementing GeNomics In pracTicE (IGNITE) network. A primary example is the influence of CYP2D6 genotype on the beneficial and adverse effects of some opioids. Clinical recommendations exist to guide drug therapy based on CYP2D6 genotype for codeine, tramadol, oxycodone and hydrocodone, although the level of supporting evidence differs by drug. Limited evidence also supports the use of genetic data to guide other medications in chronic pain therapy, including tricyclic antidepressants and celecoxib. Pragmatic clinical trial data are needed in this area to better understand the impact of diverse populations, therapeutic interventions and clinical care environments on genotype-guided drug therapy for chronic pain.

Indexed as

Analgesics, OpioidCodeineCytochrome P-450 CYP2D6GenomicsGenotypeHumansHydrocodoneOxycodonePain ManagementPharmacogeneticsPolymorphism, GeneticPrecision MedicineTramadolAnalgesics, OpioidCodeineCytochrome P-450 CYP2D6HydrocodoneOxycodoneTramadolCYP2D6implementationopioidspain managementpharmacogeneticsprimary care

Identifiers

PMID29714124
PMCPMC6460918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.